BSE Live
Mar 27, 16:01Prev. Close
1243.90
Open Price
1237.35
Bid Price (Qty.)
1239.20 (10)
Offer Price (Qty.)
1242.65 (10)
NSE Live
Mar 27, 15:58Prev. Close
1244.40
Open Price
1226.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1242.30 (203)
| Key Financial Ratios of Cipla (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 13.66 | 49.29 | |
| Diluted EPS (Rs.) | 13.66 | 49.29 | |
| Cash EPS (Rs.) | 15.50 | 56.02 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 51.47 | 209.08 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 51.81 | 210.77 | |
| Dividend / Share(Rs.) | 3.50 | 15.00 | |
| Revenue from Operations/Share (Rs.) | 75.18 | 320.65 | |
| PBDIT/Share (Rs.) | 19.25 | 75.83 | |
| PBIT/Share (Rs.) | 17.42 | 69.11 | |
| PBT/Share (Rs.) | 17.16 | 67.38 | |
| Net Profit/Share (Rs.) | 13.66 | 49.29 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 25.60 | 23.64 | |
| PBIT Margin (%) | 23.16 | 21.55 | |
| PBT Margin (%) | 22.82 | 21.01 | |
| Net Profit Margin (%) | 18.16 | 15.37 | |
| Return on Networth / Equity (%) | 26.53 | 23.57 | |
| Return on Capital Employed (%) | 22.79 | 19.57 | |
| Return on Assets (%) | 15.65 | 13.31 | |
| Total Debt/Equity (X) | 0.13 | 0.17 | |
| Asset Turnover Ratio (%) | 86.17 | 86.61 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 2.14 | 2.02 | |
| Quick Ratio (X) | 1.23 | 1.22 | |
| Inventory Turnover Ratio (X) | 3.02 | 3.38 | |
| Dividend Payout Ratio (NP) (%) | 25.62 | 30.43 | |
| Dividend Payout Ratio (CP) (%) | 22.58 | 26.77 | |
| Earnings Retention Ratio (%) | 74.38 | 69.57 | |
| Cash Earnings Retention Ratio (%) | 77.42 | 73.23 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 7,820.35 | 7,220.76 | |
| EV/Net Operating Revenue (X) | 3.47 | 3.75 | |
| EV/EBITDA (X) | 13.55 | 15.88 | |
| MarketCap/Net Operating Revenue (X) | 3.39 | 3.65 | |
| Retention Ratios (%) | 74.37 | 69.56 | |
| Price/BV (X) | 4.95 | 5.60 | |
| Price/Net Operating Revenue | 3.39 | 3.65 | |
| Earnings Yield | 0.05 | 0.04 |
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth